|
MechanismSARS-CoV-2 3CLpro inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Shaanxi Panlong Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shaanxi Panlong Pharmaceutical Co., Ltd.
100 Deals associated with Shaanxi Panlong Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shaanxi Panlong Pharmaceutical Co., Ltd.